Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | PGR | P06401 | 3/20 | 0.68 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21973842 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL19665917 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL2903879 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL14523062 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL19665918 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL15920472 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL15904751 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL17361272 | 1.00 | HIF1A (0.68) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL15920488 | 0.89 | HIF1A (0.67) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 | |
| SCHEMBL18878439 | 0.88 | HIF1A (0.71) | HIF1ANR3C2SMN1; SMN2NR3C1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5407926-A | Administering angiostatic steroid with glucocorticoid, carrier | ALCON LABORATORIES, INC. (US) | 1995-04-18 | — | — | US | claimed |
| EP-4295908-A2 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | Sage Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-07-20 | — | — | US | disclosed |
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230141665-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-1741779-A2 | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-01-10 | — | — | EP | disclosed |
| US-6998238-B2 | Method for determining MIF content | CYTOKINE PHARMASCIENCES, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| WO-2006008092-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | NOVARTIS AG (CH) | 2006-01-26 | — | — | WO | disclosed |
| US-20050187188-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY (US) | 2005-08-25 | — | — | US | disclosed |
| US-20040053843-A1 | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity | BAXTER INTERNATIONAL INC. | 2004-03-18 | — | — | US | disclosed |
| US-6645493-B1 | Treatment of disease caused by cytokine-mediated toxicity; anti-Migration Inhibitory Factor (MIF) antibody | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-11 | — | — | US | disclosed |
| US-20030099653-A1 | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity | BAXTER INTERNATIONAL INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020072509-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY | 2002-06-13 | — | — | US | disclosed |
| US-6080407-A | CYTOKINE-MEDIATED TOXICITY COMPRISING ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF AN ANTI-MACROPHAGE MIGRATION INHIBITORY FACTOR; GRAFT VERSUS HOST DISEASE, ANTISHOCK, -INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-06-27 | — | — | US | disclosed |
| US-6030615-A | Combination method for treating diseases caused by cytokine-mediated toxicity | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | NR3C2, NR3C1, HSD3B1 | HIF1A 4420/4885NR3C2 1/4885SMN1; SMN2 1102/4885 |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, CYP17A1, HSD3B1 | HIF1A 1510/4885NR3C2 16/4885SMN1; SMN2 1739/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | HIF1A 509/4885NR3C2 519/4885SMN1; SMN2 4655/4885 |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | GAP43, CYP17A1, HSD3B1 | HIF1A 1510/4885NR3C2 16/4885SMN1; SMN2 1739/4885 |
| US-20230141665-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SHBG, CRH, NR3C2 | HIF1A 3716/4885NR3C2 3/4885SMN1; SMN2 304/4885 |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, CYP21A2 | HIF1A 1543/4885NR3C2 2/4885SMN1; SMN2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.